Role of Transient Receptor Potential Vanilloid 4 in Neutrophil Activation and Acute Lung Injury

Jun Yin1,2,*, Laura Michalick3, Christine Tang2,4, Arata Tabuchi2, Neil Goldenberg2, Qinghong Dan2, Khader Awwad5, Liming Wang1,2, Lasti Erfinanda1, Geraldine Nouailles6, Martin Witzenrath7, Alexis Vogelzang7, Lu Lv1, Warren L. Lee2, Haibo Zhang*, Ori Rotstein2,8, Andras Kapus2,8, Katalin Szaszi2,8, Ingrid Fleming6, Wolfgang B. Liedtke9, Hermann Kuppe10, and Wolfgang M. Kuebler2,3,8,10

1Department of Cardiothoracic Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, China; 2Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, Ontario, Canada; 3Institute of Physiology, Charité Universitätsmedizin Berlin, Berlin, Germany; 4Department of Medicine, University of Toronto, Toronto, Ontario, Canada; 5Institute for Vascular Signaling, Center for Molecular Medicine, Goethe University Frankfurt, Frankfurt, Germany; 6Department of Infectious Diseases and Pulmonary Medicine, Charité–Universitätsmedizin Berlin, Berlin, Germany; 7Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany; 8Department of Surgery, University of Toronto, Toronto, Ontario, Canada; 9Department of Medicine/Division of Neurology, Duke Clinics for Pain and Palliative Care, Duke University Medical Center, Durham, North Carolina; and 10German Heart Institute Berlin, Berlin, Germany

Abstract

The cation channel transient receptor potential vanilloid (TRPV) 4 is expressed in endothelial and immune cells; however, its role in acute lung injury (ALI) is unclear. The functional relevance of TRPV4 was assessed in vivo, in isolated murine lungs, and in isolated neutrophils. Genetic deficiency of TRPV4 attenuated the functional, histological, and inflammatory hallmarks of acid-induced ALI. Similar protection was obtained with prophylactic administration of the TRPV4 inhibitor, GSK2193874; however, therapeutic administration of the TRPV4 inhibitor, HC-067047, after ALI induction had no beneficial effect. In isolated lungs, platelet-activating factor (PAF) increased vascular permeability in lungs perfused with trpv4−/− more than with trpv4+/− blood, independent of lung genotype, suggesting a contribution of TRPV4 on blood cells to lung vascular barrier failure. In neutrophils, TRPV4 inhibition or deficiency attenuated the PAF-induced increase in intracellular calcium. PAF induced formation of epoxyeicosatrienoic acids by neutrophils, which, in turn, stimulated TRPV4-dependent Ca2+ signaling, whereas inhibition of epoxyeicosatrienoic acid formation inhibited the Ca2+ response to PAF. TRPV4 deficiency prevented neutrophil responses to proinflammatory stimuli, including the formation of reactive oxygen species, neutrophil adhesion, and chemotaxis, putatively due to reduced activation of Rac. In chimeric mice, however, the majority of protective effects in acid-induced ALI were attributable to genetic deficiency of TRPV4 in parenchymal tissue, whereas TRPV4 deficiency in circulating blood cells primarily reduced lung myeloperoxidase activity. Our findings identify TRPV4 as novel regulator of neutrophil activation and suggest contributions of both parenchymal and neutrophilic TRPV4 in the pathophysiology of ALI.

Keywords: transient receptor potential vanilloid 4; neutrophil; acute lung injury; calcium; reactive oxygen sepsis
Clinical Relevance

The present findings identify transient receptor potential vanilloid (TRPV) 4 as a novel regulator of neutrophil activation. In addition to the principal role of parenchymal TRPV4, neutrophilic TRPV4 contributes to features of experimental acute lung injury. This contribution may be of particular relevance in scenarios of systemic inflammation and direct neutrophil activation.

Acute respiratory distress syndrome (ARDS) is defined by acute hypoxemic respiratory failure, radiographic evidence of bilateral pulmonary opacities, and pulmonary edema, not fully explained by cardiac failure or fluid overload (1). Although no longer used to refer to the overarching clinical entity in humans, the term, “acute lung injury” (ALI) remains the proper descriptor of the corresponding disease in experimental animals. With an estimated incidence of 86.2 per 100,000 person-years and mortality rates of up to approximately 43% (2), ARDS presents a major cause of mortality and morbidity in critical care. Although extensive effort has been made to develop effective therapeutic strategies, including the introduction of recruitment maneuvers, high positive end-expiratory pressure application, high-frequency oscillatory ventilation, inhaled nitric oxide, or glucocorticoid administration (reviewed in Ref. 3), the only interventions demonstrated to improve clinical outcomes in ARDS so far are the use of a protective ventilatory strategy with low tidal volumes (4) and early application of prolonged prone positioning in patients with severe ARDS (5). In contrast, none of the pharmacological interventions tested so far in clinical trials could yield a detectable benefit in terms of mortality (3).

Although numerous direct (lung-specific; e.g., pneumonia) or indirect (systemic; e.g., sepsis) inflammatory triggers can cause ALI/ARDS, the resulting pathology and pathophysiology is strikingly uniform. The characteristic hallmarks of ALI/ARDS comprise diffuse endothelial and epithelial injury, which results in lung barrier failure and formation of a proteinaceous alveolar edema, and a strong inflammatory response characterized by the release of proinflammatory cytokines and the recruitment of granulocytes, monocytes, and platelets into the lung (6).

The transient receptor potential vanilloid (TRPV) 4 channel is one of six members of the vanilloid subfamily of transient receptor potential (TRP) channels, a group of 28 polymodal cation channels with multiple sensory functions that share some structural similarity (7). TRPV4 is widely expressed in lung parenchymal and inflammatory cells involved in ALI/ARDS, including lung microvascular endothelial cells (8), lung epithelial cells (8), neutrophils (9), and macrophages (10). TRPV4 channels are 5–10 times more permeable for Ca\(^{2+}\) than for Na\(^+\), and can be activated by a wide range of both physical stimuli, including cell swelling, heat, and mechanical stimulation, as well as chemical stimuli, such as endocannabinoids and epoxyeicosatrienoic acids derived from arachidonic acid (11).

Recently, we and others have shown TRPV4 to mediate the endothelial permeability increase and subsequent lung edema formation in response to increased hydrostatic stress (12, 13) and overventilation (10). Given the key role of endothelial permeability in ALI/ARDS and the wide range of TRPV4 activators, we considered that TRPV4-mediated vascular barrier failure may equally contribute to the pathophysiology of ALI. In addition, we speculated that TRPV4 may also modulate the inflammatory response in ALI, because: (1) TRPV4 is highly expressed in human leukocytes (14) and murine neutrophils (9); (2) TRPV4 has been implicated in the proinflammatory response of alveolar macrophages (10); and (3) the closely related channel TRPV2 was recently shown to play an essential role in phagocytes (15). It was therefore the objective of the present study to investigate the effect of genetic deficiency or pharmacological inhibition of TRPV4 on experimental ALI, and to identify its mechanistic role in the underlying inflammatory and permeability responses.

Materials and Methods

Details are provided in the accompanying online supplement. In brief, ALI was induced by intratracheal instillation of hydrochloric acid in male TRPV4-deficient (trpv4\(^{-/-}\)) mice (kindly provided by W. Liedtke, Duke University), their corresponding wild types (trpv4\(^{+/+}\)), or chimeric mice generated by bone marrow transplantation between trpv4\(^{+/+}\) and trpv4\(^{-/-}\) mice after lethal irradiation. For prophylactic inhibition of TRPV4 in vivo, the specific inhibitor, GSK2193874, generously provided by GlaxoSmithKline (Research Triangle Park, NC), was injected intravenously 20 minutes before acid instillation. For all other applications, the commercially available TRPV4 inhibitor, HC-067047, was applied. As therapeutic approach, HC-067047, which we have previously shown to effectively prevent TRPV4-dependent ventilator-induced lung injury in mice (16), was administered 45 minutes after acid instillation. ALI was evaluated by measurements of quasistatic respiratory compliance, arterial oxygenation, lung edema, neutrophil influx, and histological signs of lung injury. In bronchoalveolar lavage (BAL) fluid, total protein content and inflammatory cytokine profiles were determined. In isolated, perfused mouse lungs, vascular permeability was assessed by Evan’s blue extravasation and continuous monitoring of lung weight change in the presence of platelet-activating factor (PAF) or vehicle. Ex vivo chimeras were generated by perfusion of isolated lungs with heparinized whole blood, including platelets and neutrophils from donor mice (trpv4\(^{+/+}\) or trpv4\(^{-/-}\)). Murine and human neutrophils were isolated as described previously (17, 18), and TRPV4 protein expression was determined by Western blot. The intracellular calcium concentration ([Ca\(^{2+}\)]\(_i\)) in isolated neutrophils was measured by fura-2 ratiometric imaging in the absence or presence of the TRPV4 inhibitor, HC-067047, before and after stimulation by PAF. Generation of reactive oxygen species (ROS) was quantified by luminol-enhanced chemiluminescence, neutrophil adhesion to lung microvascular endothelial cells pretreated with LPS was assessed, and neutrophil chemotaxis was determined by transwell assays. Rac activity in isolated neutrophils stimulated with PAF or vehicle (saline) was determined by an affinity precipitation assay (19) and epoxyeicosatrienoic acid (EET) profiles were quantified in cell supernatants, as previously described (20). Statistical analysis was performed by use of GraphPad Prism software (GraphPad Software Inc., 371
La Jolla, CA). Data are presented as mean (±SEM). Statistical analyses within groups were performed by Wilcoxon matched pairs signed rank test and repeated measures ANOVA on ranks (Friedman test and appropriate post hoc test). Different groups were compared by Mann-Whitney U test and ANOVA on ranks (Kruskal-Wallis test). Statistical significance was assumed at P < 0.05.

**Results**

**TRPV4 in ALI**

In wild-type (trpv4+/+) mice, instillation of hydrochloric acid caused characteristic functional features of murine ALI, including progressive arterial deoxygenation (Figure 1A), hypoxemia (Figure 1B), and reduced lung compliance (Figure 1C) after 2 hours. Lung vascular barrier failure was evident as increase in lung wet-to-dry weight ratio (Figure 1D) and BAL protein concentration (Figure 1E). Hallmarks of the lung inflammatory response were apparent as increased lung myeloperoxidase (MPO) activity, indicating influx of inflammatory neutrophils (Figure 1F) and elevated levels of the inflammatory cytokines, IL-1β, IL-6, monocyte chemotactic protein-1, keratinocyte-derived chemokine (KC), regulated upon activation, normal T cell expressed and secreted (RANTES), and macrophage inflammatory protein-2 (Figure 2). Lung injury was histologically evident in hematoxylin and eosin-stained lung sections, and quantitatively verified in blinded analyses by a lung injury score (Figures 2G and 2H).

Inhibition of TRPV4 in wild-type mice by prophyllactic intravenous infusion of the TRPV4 inhibitor, GSK2193874 (5 mg/kg), 20 minutes before acid instillation significantly attenuated all features of acid-induced ALI (i.e., improved gas exchange and lung mechanics), and reduced signs of lung vascular barrier function, lung inflammation, and histological signs of lung injury (Figures 1 and 2). The key role of TRPV4 in experimental ALI was confirmed in a genetic loss-of-function model using TRPV4-deficient (trpv4−/−) mice in which signs of ALI after acid instillation were again largely attenuated (Figures 1 and 2). Declaredly, we abstained from additional controls for pharmacological inhibition of genetic deficiency of TRPV4 in uninjured control mice, as these have recently been reported to show normal baseline characteristics of lung function, inflammation, and histology (21). Next, we tested the effects of TRPV4 inhibition in a clinically more relevant scenario, in that the TRPV4 inhibitor HC-067047 (1.6 mg/kg body weight) was administered 45 minutes after induction of ALI by acid instillation. At this time point, therapeutic TRPV4 inhibition no longer attenuated ALI, as assessed by parameters of impaired oxygenation (Figure 3A), respiratory mechanics (Figure 3B), lung barrier function (Figures 3C and 3D), neutrophil influx (Figure 3E), and histological evidence of lung injury (Figure 3F).

**Lung Vascular Barrier Regulation by TRPV4**

Based on our previously reported finding that TRPV4 is critically involved in the regulation of lung endothelial permeability, we tested for the role of TRPV4 in pulmonary vascular barrier function in isolated, buffer-perfused mouse lungs. Stimulation with PAF (5 nmol bolus, final concentration in perfusate: 1 μmol/L) significantly increased lung weight gain (Figure 4A) and Evans blue extravasation (Figure 4B) in isolated lungs from wild-type mice, indicating relevant protein and fluid leakage across the endothelium that was largely attenuated in lungs from trpv4−/− mice. Conversely, to address the contribution of TRPV4 expression on circulating blood cells, we performed chimeric cross-transfusion experiments in isolated blood-perfused lungs. Notably, whereas PAF stimulation in the buffer-perfused lung is a well established model of direct PAF-induced endothelial leak (22), PAF infusion into the blood-perfused lung presents primarily a model of PAF activation of circulating blood cells, as PAF will be rapidly deactivated by plasma PAF acetylhydrolase (23) before reaching the alveolar capillary bed. In trpv4−/− lungs perfused with trpv4+/− blood, PAF stimulation increased Evans blue extravasation as compared with unstimulated blood-perfused lungs (Figure 4C). In contrast to the results in buffer-perfused lungs, PAF-induced vascular leak was not attenuated by TRPV4 deficiency in lung parenchymal cells, but significantly reduced in lungs perfused with blood from trpv4−/− mice independent of the genotype of the perfused lung.

Perfusion pressures in these experiments increased from 13.0 (±1.0) to 21.6 (±3.4) cm H2O in response to PAF, yet did not differ between lung or blood genotypes, respectively, indicating that differences in Evans blue extravasation reflected changes in vascular permeability rather than hydrostatic pressure (data not shown). Taken together, these findings indicate that, depending on the stimulation mode, functional expression of TRPV4 on both parenchymal cells and circulating blood cells can contribute to lung vascular barrier failure.

**Role of TRPV4 in Neutrophil Function**

To our knowledge, TRPV4-dependent regulation of circulating blood cell functions has not been reported as of yet; however, previous studies have reported high expression levels of TRPV4 in human leukocytes (14) and murine neutrophils (9). Because neutrophils play a central role in the pathogenesis of ALI and lung vascular barrier failure, we speculated that TRPV4 may critically regulate neutrophil function. We first confirmed TRPV4 expression on isolated neutrophils from both human volunteers and mice (Figure 5A). Next, we tested whether TRPV4 is required for the [Ca2+]i response of neutrophils to proinflammatory stimuli. In neutrophils of trpv4+/+ mice, addition of PAF induced a transient increase in [Ca2+]i, that showed the rapid upslope characteristic for the well documented, IP3-dependent Ca2+ release from intracellular stores, and the subsequent prolonged elevation attributable to influx of extracellular Ca2+ (24). The latter component of the [Ca2+]i response was markedly reduced in neutrophils of trpv4−/− mice, or in the presence of the TRPV4 inhibitor, HC-067047 (25) (Figures 5B and 5C), demonstrating that TRPV4 was required for a sustained [Ca2+]i elevation in response to PAF. Similarly to the effects in murine cells, HC-067047 attenuated the [Ca2+]i response to PAF in human neutrophils (Figure 5D).

EETs are potent activators of TRPV4 in vascular endothelial cells (11, 26). Analogously, stimulation with 3 μmol/L 5,6-EET, a concentration previously shown to activate endothelial TRPV4 (8), increased [Ca2+]i, in murine neutrophils of wild-type mice, but significantly less so in neutrophils of trpv4−/− mice (Figure 5E). Stimulation with PAF triggered the formation of several EETs, including 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET, suggesting that TRPV4 may play a role in the regulation of neutrophil function.
in human neutrophils (Figure 5F), and cytochrome P450 epoxygenase inhibition using propargyloxyphenyl hexanoic acid (50 μMol/L) (12) attenuated the neutrophil calcium ([Ca^{2+}]_{i}) response to PAF (Figure 5G).

Taken together, these data suggest that PAF triggers a [Ca^{2+}]_{i} increase in neutrophils via formation of EETs, which, in turn, stimulate TRPV4 cation channels, allowing for sustained Ca^{2+} influx.

Next, we tested for functional downstream effects of TRPV4 activation in neutrophils. In wild-type murine cells, stimulation with PAF caused a rapid, pronounced, and sustained production of ROS characteristic of the respiratory burst of neutrophils (Figure 6A). In neutrophils of trpv4<sup>-/-</sup> mice, however, this response...
was largely attenuated. Consistent with a key role of TRPV4 in neutrophil activation, neutrophil adhesion to LPS-stimulated lung microvascular endothelial cells (Figure 6B) and neutrophil transmigration across an endothelial monolayer (Figure 6C) were markedly reduced when neutrophils were deficient in functional TRPV4 or pretreated with the TRPV4 inhibitor HC-067047. As activation of the small GTPase, Rac, constitutes a common denominator for the respiratory burst of neutrophils (27), leukocyte adhesion (28), and chemotaxis (29), and can be triggered by Ca$^{2+}$ influx (30), we probed for the role of TRPV4 in neutrophil Rac activation. In neutrophils of wild-type mice, stimulation with PAF approximately doubled the ratio of active versus total Rac, yet this effect was completely absent in neutrophils of trpv4$^{-/-}$ mice (Figures 6D and 6E), indicating that PAF-induced Rac activation in neutrophils requires TRPV4. Of note, TRPV4 deficiency did
not affect total numbers of circulating white blood cells or neutrophils in mice (Figure 6F).

**Acid-Induced Lung Injury in TRPV4 Chimeric Mice**

Finally, to probe for the relative contribution of endothelial versus neutrophilic TRPV4 in our murine model of acid-induced lung injury, we generated TRPV4 chimeric mice by bone marrow transfer from trpv4+/+ or trpv4-/- donor mice into previously lethally irradiated trpv4+/+ or trpv4-/- recipient mice, respectively. Controls without ALI did not differ between genotypes and chimeras in lung wet-to-dry-weight ratio (4.51 ± 0.05), histological lung injury score (0.084 ± 0.016), BAL protein (0.21 ± 0.01 μg/ml), and MPO activity (0.21 ± 0.05 U/mg), respectively (n = 3 per group each). Pulmonary vascular leakage in response to acid instillation, as measured by the lung wet-to-dry-weight ratio, was largely abrogated by genetic deficiency of TRPV4 in parenchymal tissue, but not by TRPV4 deficiency in circulating blood cells (Figure 7A). Similarly, histological lung injury scores did not reveal a beneficial effect of TRPV4 deficiency in circulating blood cells, whereas parenchymal TRPV4 deficiency showed similar protection as combined TRPV4 deficiency in both lung and blood cells (Figure 7B), and comparable protection as initially detected in trpv4-/- mice (Figure 2H). Selective deficiency of TRPV4 in neither parenchymal nor myeloid cells conferred significant protection against protein leakage into the BAL, whereas BAL protein content was significantly reduced in mice with complete TRPV4 deficiency (Figure 7C). In contrast, the increase in MPO activity was significantly reduced by TRPV4 deficiency in either lung parenchymal or circulating blood cells, indicating a role for both endothelial and neutrophilic TRPV4 in the accumulation of neutrophils in the acid-injured lung (Figure 7D).

**Discussion**

In the present work, we identify a critical role of the polymodal cation channel TRPV4 in the pathogenesis of ALI and in the activation of neutrophils. In a murine model of acid-induced lung injury, which mimics the clinical development of ARDS after aspiration of gastric contents (31), both genetic deficiency and prophylactic pharmacological inhibition of TRPV4 markedly attenuated the key features of experimental ALI (32) (i.e., impairment of gas exchange and lung function, inflammation, lung edema, and histological evidence of lung damage, respectively). The protective effect of TRPV4 inhibition was, however, lost when the inhibitor was administered therapeutically 45 minutes after ALI induction. Isolated, buffer-perfused lungs from trpv4-/- mice were protected from PAF-induced barrier failure, suggesting involvement of TRPV4 expressed on lung parenchymal cells; however, chimeric experiments in blood-perfused lungs revealed, in addition, a critical role of TRPV4 expression on circulating blood cells. We confirmed expression of TRPV4 on both murine and human neutrophils, and demonstrated its functional relevance for mediating the sustained neutrophil Ca2+ response to PAF. The latter was likely triggered by EETs, as the PAF-induced increase in neutrophil [Ca2+], was sensitive to a cytochrome P450 epoxygenase inhibitor. This view was substantiated by the findings that PAF triggered the formation of various bioactive EETs in neutrophils, and that exogenous 5,6-EET in turn stimulated neutrophilic TRPV4 in the accumulation of neutrophils in the acid-injured lung, indicating a role for both endothelial and neutrophilic TRPV4 in the accumulation of neutrophils in the acid-injured lung (Figure 7D).
to endothelial, not neutrophilic, TRPV4, with the latter only contributing to neutrophil accumulation, but not relevantly to vascular leak or histological signs of lung injury.

Taken together, our findings reveal a previously unrecognized role of TRPV4 in neutrophil activation and function that can contribute to some features of ALI, yet the predominant relevance of TRPV4 in ALI relates to its expression in lung parenchymal cells.

In the present study, we probed for the role of TRPV4 in experimental ALI, lung vascular leak and neutrophil activation using the well established in vivo model of acid-induced lung injury on the one hand (31), and PAF as stimulus in our in situ and in vitro experiments on the other hand. The latter choice was based on the following considerations: (1) that PAF has been implicated as an important mediator in clinical ARDS, and its blockage is protective in most experimental models of ALI (33); and (2) that PAF can activate neutrophils (24) and is concomitantly one of the few mediators that will directly and rapidly induce endothelial barrier dysfunction in the intact lung (34), which makes it ideally suited to address the individual contributions of both endothelial and neutrophilic TRPV4. However, it is important to keep in mind that in situ or in vitro stimulation with PAF, like any other single mediator, only reflects a

Figure 3. Therapeutic TRPV4 inhibition does not alleviate characteristic features of acid-induced lung injury. Group data show the effects of pharmacological TRPV4 inhibition by HC-067047 (1.6 mg/kg, delivered 45 minutes after the induction of lung injury) in a 2-hour murine model of acid (HCl)-induced ALI on $\text{SaO}_2$ (A), lung quasi-static compliance (B), lung wet-to-dry weight ratio (C), protein concentration in the BAL fluid (D); lung MPO activity as a measure of neutrophil invasion (E), and histological features of lung injury on a quantitative scale from 0 (no injury) to 1 (maximal) (F). Data are mean ± SEM from $n = 10$ mice in control, and $n = 8$ mice in HC-067047 for A–F; no significant differences were detected between groups.
simplified model of the complex scenario of ALI in vivo. Furthermore, acid-induced lung injury in vivo and PAF stimulation in isolated lungs not only differ in the complexity of the two models, but also in their site of action, in that intratracheal acid instillation primarily causes epithelial injury, whereas addition of PAF to the lung perfusate will primarily target the vascular endothelium in buffer-perfused lungs, or—due to the rapid degradation of PAF by plasma PAF acetylhydrolase (23)—the circulating blood cells in blood-perfused lungs, respectively.

TRPV4 is a widely expressed polymodal sensory cation channel that is critically involved in a broad variety of cell and organ functions, ranging from bone development to the regulation of vascular tone to renal regulation of urine output and tonicity (35). Human gene mutations in TRPV4 are associated with various forms of skeletal dysplasias and neurodegenerative diseases (36). Importantly, TRPV4 is not only expressed on the key cell types involved in the pathogenesis of ALI (i.e., lung endothelial [8] and epithelial [8] cells, as well as alveolar macrophages [10] and neutrophils [9]), but also functionally regulates cellular responses that are considered characteristic hallmarks in the pathogenesis of ALI (37), such as lung endothelial barrier failure (12, 13) and macrophage activation (10). We therefore postulated that TRPV4 may contribute relevantly to ALI, and confirmed this hypothesis by demonstrating that genetic deficiency or pharmacological inhibition of TRPV4 largely attenuated the classic features of organ damage (i.e., loss of function, inflammation, and permeability edema) in a murine model of acid-induced ALI. Whereas the blocker potency of the applied TRPV4 inhibitor, GSK2193874, is lower by approximately a factor of 10 in human as compared with murine or rat TRPV4, its close analog, GSK2263095, has a comparable half maximal inhibitory concentration (IC50) for human TRPV4.

**Figure 4.** The role of TRPV4 in vascular barrier failure of blood-perfused lungs is partially attributable to its expression on circulating blood cells. Isolated, buffer-perfused lungs of TRPV4-deficient (trpv4+/−) or corresponding WT mice were stimulated with a bolus of platelet-activating factor (PAF; 5 nmol; final concentration in perfusate: 1 μmol/L) or vehicle (DMSO; control), and vascular barrier failure was assessed as either increase in total lung weight (A) or as extravasation of Evans blue (B), respectively. For chimeric experiments, isolated lungs from either trpv4−/− or WT mice were perfused with heparinized whole blood from trpv4−/− or WT mice, respectively, and barrier failure in response to PAF bolus infusion (5 nmol) was determined as Evans blue extravasation (C). Data are mean ± SEM from n = 5 and 7 lungs per group in A and B, and n = 3 for controls and n = 7 for PAF groups in C, respectively. *P < 0.05 versus control; #P < 0.05 versus corresponding WT lungs (A and B) or between different blood genotypes as indicated (C).
(3 nM), as GSK2193874 does for murine and rat TRPV4 (2–5 nM) after stimulation with the selective TRPV4 agonist, GSK634775 (38). Although this renders the use of TRPV4 blockers for the prevention and/or treatment of clinical ARDS a realistic possibility, therapeutic administration of a TRPV4 inhibitor did not prove successful in attenuating ALI when administered 45 minutes after intratracheal acid instillation. This result is somewhat surprising, given that

![Figure 5](image-url)

**Figure 5.** TRPV4 mediates the neutrophil calcium response to PAF. Western blot analyses show expression of TRPV4 in isolated neutrophils (A). Representative tracings (B) and group data (C; as area-under-the-curve over baseline for 5 minutes) show intracellular calcium concentration ([Ca²⁺]ᵢ) response to PAF (10 μmol/L) stimulation in murine neutrophils from WT mice in the absence or presence of the TRPV4 inhibitor, HC-067047 (20 μmol/L), or in neutrophils isolated from TRPV4-deficient (trpv4⁻/⁻) mice, and in human neutrophils in the presence or absence of HC-067047 (D). Group data show [Ca²⁺]ᵢ response to PAF (10 μmol/L) stimulation in murine neutrophils from WT mice in the absence or presence of the TRPV4 inhibitor, HC-067047 (20 μmol/L), or in neutrophils isolated from TRPV4-deficient (trpv4⁻/⁻) mice, and in human neutrophils in the presence or absence of HC-067047 (D). Group data show [Ca²⁺]ᵢ response to 5,6-epoxyeicosatrienoic acid (EET; 3 μmol/L) in murine neutrophils from WT and trpv4⁻/⁻ mice (E), and formation of the regioisomers 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET in human neutrophils after 5-minute stimulation with PAF (10 μmol/L; F). Group data show [Ca²⁺]ᵢ response to PAF (10 μmol/L) in human neutrophils in the presence or absence of the cytochrome P450 epoxygenase inhibitor, propargyloxyphenylhexanoic acid (PPOH; 50 μMol/L) (G). Data are mean ± SEM from n = 6 per group in C–E and G, and n = 4 per group in F. *P < 0.05 versus WT PAF (C), PAF (D and G), 5,6-EET WT (E), or control (F), respectively.
intrapleural administration of a TRPV4 antagonist 30 minutes after acid instillation had recently been shown to yield considerable therapeutic effectiveness in a similar model of acid-induced lung injury (21). At the present stage, we can only speculate as to the causes underlying these discrepant findings. The most notable difference is the actual TRPV4 inhibitor itself, which, in the previous study by Balakrishna and colleagues (21), was the TRPV4 antagonist, GSK2220691, whereas our study used the commercially available TRPV4 inhibitor, HC-067047 (25). Notably, we had previously used this inhibitor successfully in an in vivo model of murine ventilator-induced lung injury, where it conveyed protection similar to genetic TRPV4 deficiency when given at a similar dose and by similar route, as in the present study (16). Hence, it seems that therapeutic administration of TRPV4 inhibitors may alleviate lung injury in some, but not all, experimental models, and that further studies in different disease models and species are needed before translation of this approach to the clinical scenario.

Based on previous findings by us (13) and others (39), which have demonstrated an important role of TRPV4 in the regulation of lung vascular barrier integrity, we initially hypothesized that the protective effect of TRPV4 inhibition or deficiency in experimental ALI was predominantly attributable to its expression on lung microvascular endothelial cells. We tested this concept in isolated, perfused lungs by measuring the lung vascular barrier response to PAF, one of the few mediators that can increase pulmonary vascular permeability within minutes in the absence of inflammatory blood cells (34). Initial experiments in isolated, buffer-perfused lungs confirmed this notion, insofar as lung weight gain and Evans blue extravasation in response to PAF were largely prevented in lungs of trpv4−/− mice. Notably, PAF-induced increases in lung perfusion pressure did not differ between genotypes, confirming that differences in fluid accumulation and leak reflected TRPV4-dependent changes in lung vascular permeability rather than hydrostatic pressure. Unexpectedly, however, subsequent chimeric experiments in blood-perfused, isolated lungs identified TRPV4 expression on circulating blood cells as additional putative mechanism of PAF-induced lung vascular barrier failure, in that PAF-induced Evans blue extravasation was largely blocked when lungs were perfused with trpv4−/− blood, independent of the actual lung genotype. Importantly, although the buffer-perfused lung is a well established model of direct PAF-activated Evans blue extravasation, subsequent studies confirmed that this model was not sufficient in experimental models and species are needed before translation of this approach to the clinical scenario.
experiments in blood-perfused lungs identified an additional putative role for TRPV4 expression in circulating blood cells. The latter finding is in line with a series of studies demonstrating that microvascular leakage in ALI in vivo critically depends on the presence and function of circulating neutrophils, as vascular barrier failure and the development of a proteinaceous permeability edema are largely attenuated by neutrophil depletion or inhibition of neutrophil elastase in various models of experimental ALI (40–41).

Based on this notion, we probed for a potential functional role of TRPV4 in neutrophils that may be relevant to the pathogenesis of ALI. TRPV4 mRNA is highly expressed as compared with other channels of the transient receptor potential canonical (TRPC) or transient receptor potential melastatin (TRPM) subfamily in murine neutrophils (9) and has also been detected in human leukocytes (14); however, its relevance for neutrophil function and activation has so far not been elucidated. In the present study, we confirmed TRPV4 expression on both murine and human neutrophils at the protein level. We next demonstrated that the previously documented characteristic 

![Figure 7](image-url)

Figure 7. Role of TRPV4 in acid-induced ALI relates primarily to TRPV4 expression on lung parenchymal rather than circulating blood cells. Group data show the effects of parenchymal (recipient) or myeloid (bone marrow) TRPV4 deficiency (trpv4−/−) versus WT on lung wet-to-dry-weight ratio (A), histological features of lung injury on a quantitative scale from 0 (no injury) to 1 (maximal) (B), protein concentration in the BAL fluid (C), and lung MPO activity as a measure of neutrophil invasion (D). Data are mean ± SEM from n = 6 mice per group in A and B, n = 7 in C and D. *P < 0.05 versus WT recipients with WT bone marrow (BM); #P < 0.05 versus WT recipients with trpv4−/− bone marrow.
TRPM2, TRPC6 (9), TRPC1, and TRPV1. There is considerable overlap of the functional effects of different TRP channels in virtually every biological system studied so far, which has led to the recognition that different TRP channels may either be functionally or structurally coupled, or that functional TRP channels may occasionally be heteromers composed of different TRP channel subunits (43). The extent to which TRPV4 may cooperate with other TRP channels or TRP subunits in the regulation of neutrophil Ca\(^{2+}\) influx and downstream signaling pathways thus presents an intriguing field for further studies.

In vascular endothelial cells, TRPV4 is potently activated by EETs, in particular by the regioisomers, 5,6-EET and 8,9-EET (11, 26). Here, we demonstrate that TRPV4 is equally stimulated by 5,6-EET in neutrophils. PAF has previously been shown to stimulate EET formation in platelets (44), and we detected an analogous increase in various EET regioisomers in neutrophils. The obvious conclusion, that the neutrophil \(\text{Ca}^{2+}\), response to PAF may be triggered by an EET-dependent activation of TRPV4, was confirmed in that inhibition of EET formation by the cytochrome P450 epoxygenase inactivator, propargyloxyphenyl hexanoic acid, largely attenuated the PAF-induced increase in neutrophil \(\text{Ca}^{2+}\),. This result is in line with the previously reported inhibition of PAF-induced \(\text{Ca}^{2+}\)-influx into neutrophils by various cytochrome P450 inhibitors (45), and with our present finding that the neutrophil \(\text{Ca}^{2+}\), response to 5,6-EET was reduced by over 50% in trpv4\(^{-/-}\) cells.

Increases in neutrophil \(\text{Ca}^{2+}\), due to \(\text{Ca}^{2+}\) mobilization from intracellular stores and/or influx of extracellular \(\text{Ca}^{2+}\), are important regulators of neutrophil function in that they are required for the effective activation of neutrophil reduced nicotinamide adenine dinucleotide phosphate oxidase and the subsequent release of superoxide anions, as well as for unimpaired neutrophil migration and chemotaxis in response to various proinflammatory stimuli. Here, we demonstrate that ROS production in response to PAF, and cell adhesion to and chemotaxis across endothelial cells, are markedly attenuated in neutrophils of trpv4\(^{-/-}\) as compared with wild-type mice. This finding is in line with an important role of neutrophil \(\text{Ca}^{2+}\),, signaling in these responses, and identifies TRPV4 as a key regulatory cation channel in neutrophil activation and migration. Ca\(^{2+}\)-dependent activation of the small GTPase Rac may link these cellular responses to TRPV4-mediated \(\text{Ca}^{2+}\), signaling, as Rac activation in response to PAF was found to be completely prevented in trpv4\(^{-/-}\) neutrophils. Because both reduced nicotinamide adenine dinucleotide phosphate oxidase activation (27) and chemotaxis (29) in neutrophils essentially require activated Rac, TRPV4-dependent Rac activation may constitute a unifying master regulator of the various neutrophil responses to proinflammatory stimuli. Of note, TRPV4 may also modulate cellular responses via direct protein–protein interaction, independent from its function as \(\text{Ca}^{2+}\), channel (46), giving rise to the alternative or additional possibility that TRPV4-mediated \(\text{Ca}^{2+}\), signaling and TRPV4-dependent activation of Rac and modulation of neutrophil functions may not necessarily be causally linked. That notwithstanding, the demonstrated role of TRPV4 in Rac activation is potentially of functional relevance in ALI, as pharmacological inhibition of Rac by NSC23766 was recently shown to inhibit neutrophil transwell migration \textit{in vitro}, and attenuated murine lung injury after intratracheal LPS challenge \textit{in vivo} (47).

Notably, TRPV4 blockade was recently shown to protect against experimental colitis in mice (48), whereas, conversely, TRPV4 agonists triggered joint inflammation in rats (49), suggesting a potentially more generalized role of TRPV4 in inflammatory disease processes. Modulation of \(\text{Ca}^{2+}\), signaling and subsequent inhibition of \(\text{Ca}^{2+}\)-dependent proinflammatory activities in neutrophils has recently gained significant interest as potential strategy to pharmacologically control autoaggressive immune reactions (50). The present identification of TRPV4 as an important regulator of neutrophil responses to proinflammatory stimuli and the recent emergence of specific pharmacological blockers of TRPV4 may therefore open new avenues for a better control of neutrophil-mediated inflammatory processes.

Although TRPV4 thus emerged as an important regulator of neutrophil activation \textit{in vitro}, this role proved, however, of limited pathophysiological relevance in the murine model of acid-induced lung injury, as protection in bone marrow chimeras was largely dependent on TRPV4 deficiency on lung parenchymal cells rather than circulating blood cells. Only MPO activity was attenuated in irradiated trpv4\(^{-/-}\) mice reconstituted with trpv4\(^{-/-}\) bone marrow, suggesting a role for TRPV4 in neutrophil adhesion and emigration in line with our \textit{in vitro} findings. Our finding that parenchymal TRPV4 has a pivotal role in the pathophysiology of ALI is consistent with previous reports that had identified TRPV4 on endothelial cells as a critical regulator of lung vascular permeability (8). Along these lines, a couple of elegant studies recently demonstrated a key role for TRPV4 in the pathogenesis of cardiogenic lung edema (38) and ALI after chlorine gas inhalation (21), respectively, and the effective attenuation of these pathologies by therapeutic administration of pharmacological TRPV4 antagonists. Although TRPV4 has thus emerged as a putative therapeutic target in both hydrostatic and permeability-type lung edema, its role in these scenarios has been almost exclusively related to its expression on the pulmonary endothelium, and did not take into account a potential contribution of myeloid TRPV4. In the present study, TRPV4 on circulating blood cells effectively modulated lung vascular permeability in isolated, blood-perfused mouse lungs, yet only affected neutrophil accumulation, but not functional or histological parameters of lung injury in chimeric mice \textit{in vivo}.

Notably, the latter experiments were performed in the murine model of acid-induced ALI (i.e., in a scenario that is predominantly characterized by epithelial injury, and a secondary inflammatory response rather than direct activation of intravascular neutrophils [31]). Hence, although these data suggest only a minor role for neutrophilic TRPV4 in acid-induced ALI, they do not preclude a more prominent role in animal models or clinical conditions of more direct (systemic) neutrophil activation as simulated in our model of PAF.
References


45. Montero M, Garcia-Sancho J, Alvarez J. Comparative effects of cytochrome P-450 inhibitors on Ca2+ and Mn2+ entry induced by agonists or by emptying the Ca2+ stores of human neutrophils. Biochim Biophys Acta 1993;1177:127–133.